PDF(Pubmed)
Abstract：
BACKGROUND: Platelet dysfunction plays a critical role in the pathogenesis of inflammatory bowel disease (IBD). Despite clinical observations indicating abnormalities in platelet parameters among IBD patients, inconsistencies persist, and these parameters lack standardization for diagnosis or clinical assessment.
METHODS: A comprehensive search was conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases for relevant articles published up to December 16th, 2023. A random-effects model was employed to pool the weighted mean difference (WMD) and 95% confidence interval (95% CI) of platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) between IBD patients and healthy controls, and subgroup analyses were performed.
RESULTS: The meta-analysis included 79 articles with 8,350 IBD patients and 13,181 healthy individuals. The results revealed significantly increased PLT and PCT levels (WMD: 69.910, 95% CI: 62.177, 77.643 109/L; WMD: 0.046%, 95% CI: 0.031%, 0.061%), and decreased MPV levels (WMD: -0.912, 95% CI: -1.086, -0.739 fL) in IBD patients compared to healthy individuals. No significant difference was found in PDW between the IBD and control groups (WMD: -0.207%, 95% CI: -0.655%, 0.241%). Subgroup analysis by disease type and disease activity showed no change in the differences for PLT, PCT, and MPV in the ulcerative colitis and Crohn\'s disease groups, as well as the active and inactive groups. Notably, the active group exhibited significantly lower PDW levels than the control group (WMD: -1.138%, 95% CI: -1.535%, -0.741%).
CONCLUSIONS: Compared with healthy individuals, IBD patients display significantly higher PLT and PCT and significantly lower MPV. Monitoring the clinical manifestations of platelet abnormalities serves as a valuable means to obtain diagnostic and prognostic information. Conversely, proactive measures should be taken to prevent the consequences of platelet abnormalities in individuals with IBD.
BACKGROUND: PROSPERO CRD42023493848.
METHODS: A comprehensive search was conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases for relevant articles published up to December 16th, 2023. A random-effects model was employed to pool the weighted mean difference (WMD) and 95% confidence interval (95% CI) of platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) between IBD patients and healthy controls, and subgroup analyses were performed.
RESULTS: The meta-analysis included 79 articles with 8,350 IBD patients and 13,181 healthy individuals. The results revealed significantly increased PLT and PCT levels (WMD: 69.910, 95% CI: 62.177, 77.643 109/L; WMD: 0.046%, 95% CI: 0.031%, 0.061%), and decreased MPV levels (WMD: -0.912, 95% CI: -1.086, -0.739 fL) in IBD patients compared to healthy individuals. No significant difference was found in PDW between the IBD and control groups (WMD: -0.207%, 95% CI: -0.655%, 0.241%). Subgroup analysis by disease type and disease activity showed no change in the differences for PLT, PCT, and MPV in the ulcerative colitis and Crohn\'s disease groups, as well as the active and inactive groups. Notably, the active group exhibited significantly lower PDW levels than the control group (WMD: -1.138%, 95% CI: -1.535%, -0.741%).
CONCLUSIONS: Compared with healthy individuals, IBD patients display significantly higher PLT and PCT and significantly lower MPV. Monitoring the clinical manifestations of platelet abnormalities serves as a valuable means to obtain diagnostic and prognostic information. Conversely, proactive measures should be taken to prevent the consequences of platelet abnormalities in individuals with IBD.
BACKGROUND: PROSPERO CRD42023493848.
摘要：
背景：血小板功能障碍在炎症性肠病（IBD）的发病机制中起着至关重要的作用。尽管临床观察表明IBD患者的血小板参数异常，不一致仍然存在，这些参数缺乏诊断或临床评估的标准化。
方法：在PubMed中进行了全面搜索，Embase,WebofScience,和Cochrane图书馆数据库的相关文章发表到12月16日，2023年。采用随机效应模型汇集血小板计数（PLT）的加权平均差（WMD）和95％置信区间（95％CI），平均血小板体积（MPV），血小板分布宽度（PDW），IBD患者和健康对照者之间的血小板（PCT），进行亚组分析.
结果：荟萃分析包括79篇文章，其中8,350例IBD患者和13,181例健康个体。结果显示PLT和PCT水平显著升高(WMD:69.910,95%CI:62.177,77.643109/L;WMD:0.046%,95%CI:0.031%,0.061%)，与健康个体相比，IBD患者的MPV水平降低（WMD：-0.912，95％CI：-1.086，-0.739fL）。IBD组和对照组之间的PDW没有显着差异（WMD：-0.207%，95%CI：-0.655%，0.241%）。按疾病类型和疾病活动的亚组分析显示PLT的差异没有变化，PCT,和MPV在溃疡性结肠炎和克罗恩病组中，以及活跃和不活跃的群体。值得注意的是,活性组的PDW水平明显低于对照组（WMD：-1.138%，95%CI：-1.535％，-0.741%）。
结论：与健康个体相比，IBD患者表现出显著较高的PLT和PCT和显著较低的MPV。监测血小板异常的临床表现是获得诊断和预后信息的有价值的手段。相反，应采取积极措施预防IBD患者血小板异常的后果.
背景：PROSPEROCRD42023493848.
方法：在PubMed中进行了全面搜索，Embase,WebofScience,和Cochrane图书馆数据库的相关文章发表到12月16日，2023年。采用随机效应模型汇集血小板计数（PLT）的加权平均差（WMD）和95％置信区间（95％CI），平均血小板体积（MPV），血小板分布宽度（PDW），IBD患者和健康对照者之间的血小板（PCT），进行亚组分析.
结果：荟萃分析包括79篇文章，其中8,350例IBD患者和13,181例健康个体。结果显示PLT和PCT水平显著升高(WMD:69.910,95%CI:62.177,77.643109/L;WMD:0.046%,95%CI:0.031%,0.061%)，与健康个体相比，IBD患者的MPV水平降低（WMD：-0.912，95％CI：-1.086，-0.739fL）。IBD组和对照组之间的PDW没有显着差异（WMD：-0.207%，95%CI：-0.655%，0.241%）。按疾病类型和疾病活动的亚组分析显示PLT的差异没有变化，PCT,和MPV在溃疡性结肠炎和克罗恩病组中，以及活跃和不活跃的群体。值得注意的是,活性组的PDW水平明显低于对照组（WMD：-1.138%，95%CI：-1.535％，-0.741%）。
结论：与健康个体相比，IBD患者表现出显著较高的PLT和PCT和显著较低的MPV。监测血小板异常的临床表现是获得诊断和预后信息的有价值的手段。相反，应采取积极措施预防IBD患者血小板异常的后果.
背景：PROSPEROCRD42023493848.
